Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Ipilimumab and Nivolumab in High-risk Ocular Melanoma
NCT03528408Phase 2Unknown
- Start
- Jul 2018
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Ocular melanoma (OM). Status: unknown.
02
Drugs
nivolumabipilimumab
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT03528408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03528408.